HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs ...

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...

Lenacapavir, a twice-yearly injectable, offers a new HIV prevention method, improving adherence compared to more frequent regimens. Phase 3 trials showed lenacapavir's high efficacy in preventing HIV, ...